PERSPECTA

News from every angle

← Back to headlines

Aclaris Therapeutics Receives Fast-Track Designation for Modzatinib

Aclaris Therapeutics has been granted Fast-Track Designation for its inflammation treatment, Modzatinib, by regulatory authorities.

6 Aug, 21:58 — 6 Aug, 21:58
PostShare

Sources

Showing 1 of 1 sources
morningstar11d ago

Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib - Morningstar

Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib  Morningstar

Read full article →

Related Stories

Canadian Home Prices Rise in July as New Listings Slow

24m ago

Pimco Executive Notes Wealth Firms' Retreat from Private Credit

28m ago

Dangote Refinery Secures $1 Billion Backing for Planned IPO

31m ago

Salmonella Outbreak Leads to Recall of 40,000 Eggs from Finnish Farm

34m ago